Announcement no. 12/2008
To the NASDAQ OMX Nordic Exchange Copenhagen Copenhagen, July 15 , 2008
Major shareholder announcement
Pursuant to section 29 of the Danish Securities Trading Act and section 28a of
the Danish Public Companies Act, notice is hereby given that as at 15 July 2008
IPC International PLC, Berkeley, Square House 2nd floor, London W1J 6BD, United
Kingdom, has changed its shareholding in Curalogic A/S to 9,760,016 shares with
a nominal value of DKK 0,50 per share.
IPC International PLC subsequently holds a total of 17.28% of the shares and
17.28% of the votes in Curalogic A/S.
Yours sincerely,
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO, Phone +45 99 99 24 01
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on NASDAQ OMX Nordic
Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash
resources and has demonstrated its ability to conduct complex clinical studies
with a small group of development experts. Curalogic has initiated a search
process to identify development projects offering an attractive risk profile.
Curalogic expects to conclude an agreement during 2008 that will secure future
clinical development projects for the Company.
This announcement contains forward-looking statements regarding the Company's
future financial development and performance and other statements which are not
historical facts. Such statements are made on the basis of assumptions and
expectations which, to the best of the Company's knowledge and belief, are
reasonable, at this time, but may prove to be erroneous in the future.
